Skip to main content
Premium Trial:

Request an Annual Quote

Cerba Research, ACT Genomics to Open Joint Lab Facility in Taiwan

NEW YORK – Cerba Research and ACT Genomics said on Tuesday that they have formed a joint venture to provide clinical trial services to clients throughout Asia Pacific through a new laboratory facility in Taiwan.

Ongoing construction, technology transfers, and expansion of the scientific team are expected to enable the facility, called CerbACT Asia Laboratory and located in Taipei, to become operational in September.

Services to be provided by the new lab include flow cytometry, in vitro diagnostic histopathology, and peripheral blood mononuclear cell isolation from blood and soft tissues.

"We will support our customers with the latest instrumentation and automation — backed by experienced scientists whose ambition and agility to meet patients’ needs drive our continuous evolution as a company," Mario Papillon, CEO of Cerba Research, a clinical trial service provider owned by Cerba HealthCare, said in a statement.

"Together, we offer a broader range of top-notch technologies and services in Asia," said Hua Chien Chen, CEO of ACT Genomics. "The formation of CerbACT Asia echoes our firm dedication in the well-being of cancer patients, keen commitment to society, and unequivocal embrace of precision medicine."

ACT Genomics, headquartered in Taiwan, provides cancer treatment planning, immunotherapy evaluation, cancer relapse and drug resistance monitoring, and cancer risk assessment services based on next-generation sequencing assays and bioinformatics analysis. Last month, the company acquired UK-based diagnostics firm MC Diagnostics.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.